U.S. Markets open in 4 hrs 37 mins

Don't Sell Immunodiagnostic Systems Holdings PLC (LON:IDH) Before You Read This

Simply Wall St

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We'll show how you can use Immunodiagnostic Systems Holdings PLC's (LON:IDH) P/E ratio to inform your assessment of the investment opportunity. Immunodiagnostic Systems Holdings has a P/E ratio of 72.95, based on the last twelve months. That is equivalent to an earnings yield of about 1.4%.

Check out our latest analysis for Immunodiagnostic Systems Holdings

How Do You Calculate A P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for Immunodiagnostic Systems Holdings:

P/E of 72.95 = £2 ÷ £0.027 (Based on the trailing twelve months to March 2019.)

Is A High Price-to-Earnings Ratio Good?

A higher P/E ratio means that buyers have to pay a higher price for each £1 the company has earned over the last year. That is not a good or a bad thing per se, but a high P/E does imply buyers are optimistic about the future.

Does Immunodiagnostic Systems Holdings Have A Relatively High Or Low P/E For Its Industry?

The P/E ratio essentially measures market expectations of a company. You can see in the image below that the average P/E (25.7) for companies in the medical equipment industry is lower than Immunodiagnostic Systems Holdings's P/E.

AIM:IDH Price Estimation Relative to Market, September 17th 2019

That means that the market expects Immunodiagnostic Systems Holdings will outperform other companies in its industry. Clearly the market expects growth, but it isn't guaranteed. So further research is always essential. I often monitor director buying and selling.

How Growth Rates Impact P/E Ratios

Generally speaking the rate of earnings growth has a profound impact on a company's P/E multiple. That's because companies that grow earnings per share quickly will rapidly increase the 'E' in the equation. That means even if the current P/E is high, it will reduce over time if the share price stays flat. And as that P/E ratio drops, the company will look cheap, unless its share price increases.

Immunodiagnostic Systems Holdings shrunk earnings per share by 34% over the last year. And over the longer term (5 years) earnings per share have decreased 35% annually. This might lead to muted expectations.

A Limitation: P/E Ratios Ignore Debt and Cash In The Bank

The 'Price' in P/E reflects the market capitalization of the company. So it won't reflect the advantage of cash, or disadvantage of debt. In theory, a company can lower its future P/E ratio by using cash or debt to invest in growth.

While growth expenditure doesn't always pay off, the point is that it is a good option to have; but one that the P/E ratio ignores.

How Does Immunodiagnostic Systems Holdings's Debt Impact Its P/E Ratio?

With net cash of UK£28m, Immunodiagnostic Systems Holdings has a very strong balance sheet, which may be important for its business. Having said that, at 48% of its market capitalization the cash hoard would contribute towards a higher P/E ratio.

The Verdict On Immunodiagnostic Systems Holdings's P/E Ratio

With a P/E ratio of 73, Immunodiagnostic Systems Holdings is expected to grow earnings very strongly in the years to come. Falling earnings per share is probably keeping traditional value investors away, but the net cash position means the company has time to improve: and the high P/E suggests the market thinks it will.

Investors have an opportunity when market expectations about a stock are wrong. People often underestimate remarkable growth -- so investors can make money when fast growth is not fully appreciated. Although we don't have analyst forecasts, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

Of course you might be able to find a better stock than Immunodiagnostic Systems Holdings. So you may wish to see this free collection of other companies that have grown earnings strongly.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.